Since 2011, 10 agents have been approved for the treatment of metastatic melanoma including two programmed cell death protein-1 (PD-1) antibodies, pembrolizumab and nivolumab, which are approved for treatment of metastatic melanoma as front-line therapy [1]. The gene discussed is PDCD1; the disease is metastatic melanoma.